Cell sampling device
View Patent ↗A swallowable cell sampling device comprising an abrasive material capable of collecting cells from the surface of the oesophagus is described. The swallowable cell sampling device may include an apparatus for retrieval comprising a cord. Moreover, the cord may be attached to the abrasive material with a hitch knot. Additionally, kits and methods involving the same are described.
1. A swallowable cell sampling device comprising:
an abrasive and sponge-like material capable of collecting cells from a surface of a human esophagus;
a means for retrieval comprising a cord;
an attachment loop formed by looping the cord around a central portion of the abrasive material; and
a hitch knot adjustably securing the attachment loop such that during retrieval of the cell sampling device, tightening of the attachment loop compresses the central portion of the abrasive material while an outer diameter of the abrasive material remains substantially constant.
2. The device according to claim 1 , wherein the hitch knot is a double overhand knot.
3. The device according to claim 1 , wherein the abrasive material is compressible.
4. The device according to claim 1 , wherein the abrasive material comprises reticulated polyurethane.
5. The device according to claim 1 , wherein the abrasive material is compressed and wherein the abrasive material is retained in a compressed state by a soluble capsule.
6. The device according to claim 5 , wherein the soluble capsule comprises a gelatin capsule.
7. The device according to claim 6 , wherein the capsule is capable of dissolution and the abrasive material is capable of reverting to its uncompressed size within 5 minutes upon immersion in water at 30 degrees Celsius.
8. The device according to claim 1 , wherein the cell sampling device further comprises an unswallowable element coupled with the cord at an end distal from the abrasive material.
9. A kit comprising a device according to claim 1 , and at least one reagent for use in detecting a cellular marker.
10. The kit according to claim 9 , wherein the cellular marker is selected from the group consisting of Mcm2 and TFF3.
11. The kit according to claim 9 , wherein the cellular marker is selected from the group consisting of ABP1, DCC, HOX C10, KCNE3, LAMC2m MUC13, MUC17, NMUR2, PICR, TCPAN1, and HOXB5.
12. The kit according to claim 9 wherein the cellular marker is selected from the group consisting of RNF2I7, CCL28, AGR3, CFTR, PAQR5, BNIP3, GOLM1, PLA2G10, KCNK5, MLSTD1, slc16a7, NFE2L2, CGNL1, CALML4, ACSL5, KRT8, TMC7, FAT, CES3, SLAC7A7, REG4, CATSPERB, TSPAN3, SLC37A1, GPRC5A, GPT2, PAIP2B, TRIM29, IL18, HSD17B11, GSDML, TACSTD1, HSD17B2, KRT7, CLIC6, ATP2C2, HEPH, TPD52L1, HOXB6, PLS1, IL1RN, NT5E, CAB39L, S100A14, GDA, TRIM31, ARPC1B, SLC16A1, TMC5, CPEB2, LOC93432, FS, VLDLR, GCNT3, MBOAT2, CPS1, GALM, DGKD, FAM102B, LYN, SFN, GALNT7, EMP1, CSTB, RHOC, F1114959, SNRPN, ANKS4B, PCLKC, ADH7, LYZ, S100A16, SLC6A20, SCNN1G, HKDC1, SLC7A2, SPG20, 37681, FGFBP1, CA9, RDX,SAMD9, RDX, SAMD9, SERPINB5, NMU, CLRN3, SLC9A4, VTCN1, LOC339977, FUT9, GALNT5, NR5A2, OLFM4, LY75, SCPEP1, TACSTD2, MYO1A, BTNL8, VIL1, SLC28A2, DPP4, AZGP1, CDH17, NPNT, ALDH1AI, ATP13A4, ATP7B, IL2RG, POSTN, FCGBP, GPA33, DSC2, COL6A3, VNN1, SLP1, AIM1, PRKAA2, GUCY2C, P13, TIMP1, APOL1, ANPEP, SLC34A2, DMBT1, RGS2, PAPSS2, BCM01, ADH6, TM4SF20, CHST5, HHLA2, FABP1, SNORD116-21, MYO7B, MIA, MEP1A, SLC3AI, PLACE, TFPI, PGC, MUC2, LIPF, FABP2, SI, SLC17A4, GSTA1, PDZK1, RAB3B, REGIA, SPINK4, CXCL1, GKN1, BTNL3, ADH4, ALDOB, CXCL2, SLC263, MMPI, UPK1B, MEP1B, CA1, and PRSS7.
13. A method for aiding a diagnosis of Barrett's esophagus or Barrett's associated dysplasia in a subject, the method comprising collecting cells from a surface of an esophagus of the subject with a device according to claim 1 and assaying the cells for a cellular marker, wherein detection of such a marker indicates increased likelihood of a presence of Barrett's esophagus or Barrett's associated dysplasia.
14. The method of claim 13 , wherein the cellular marker is selected from the group consisting of Mcm2 and TFF3.
15. The method of claim 13 , wherein the cellular marker is selected from the group consisting of ABP1, DCC, HOX C10, KCNE3, LAMC2m MUC13, MUC17, NMUR2, PICR, TCPAN1, and HOXB5.
16. The method of claim 13 , wherein the cellular marker is selected from the group consisting of RNF217, CCL28, AGR3, CFTR, PAQR5, BNIP3, GOLM1, PLA2G10, KCNK5, MLSTD1, slc16a7, NFE2L2, CGNL1, CALML4, ACSL5, KRT8, TMC7, FAT, CES3, SLAC7A7, REG4, CATSPERB, TSPAN3, SLC37A1, GPRC5A, GPT2, PAIP2B, TRIM29, IL18, HSD17B11, GSDML, TACSTD1, HSD17B2, KRT7, CLIC6, ATP2C2, HEPH, TPD52L1, HOXB6, PLS1, URN, NT5E, CAB39L, S100A14, GDA, TRIM31, ARPCIB, SLC16A1, TMC5, CPEB2, LOC93432, FS, VLDLR, GCNT3, MBOAT2, CPS1, GALM, DGKD, FAM102B, LYN, SFN, GALNT7, EMP1, CSTB, RHOC, FLJ14959, SNRPN, ANKS4B, PCLKC, ADH7, LYZ, S100A16, SLC6A20, SCNN1G, HKDC1, SLC7A2, SPG20, 37681, FGFBP1, CA9, RDX, SAMD9, RDX, SAMD9, SERPINB5, NMU, CLRN3, SLC9A4, VTCN1, LOC339977, FUT9, GALNT5, NR5A2, OLFM4, LY75, SCPEPI, TACSTD2, MYO1A, BTNL8, VIL1, SLC28A2, DPP4, AZGP1, CDH17, NPNT, ALDH1A1, ATP13A4, ATP7B, IL2RG, POSTN, FCGBP, GPA33, DSC2, COL6A3, VNN1, SLP1, AIM1, PRKAA2, GUCY2C, P13, TIMP1, APOL1, ANPEP, SLC34A2, DMBT1, RGS2, PAPSS2, BCM01, ADH6, TM4SF20, CHST5, HHLA2, FABP1, SNORD1 16-21, MYO7B, MIA, MEP1A, SLC3AI, PLAC8, TFPI, PGC, MUC2, LIPF, FABP2, SI, SLC17A4, GSTA1, PDZK1, RAB3B, REG1A, SPINK4, CXCL1, GKN1, BTNL3, ADH4, ALDOB, CXCL2, SLC26A3, MMPI, UPK1B, MEP1B, CA1, and PRSS7.